Hemostemix Adds the Treatment of Refractory Angina to Its Phase 1 Basket Protocol
Calgary, Alberta--(Newsfile Corp. - October 15, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, is pleased to annou
Biotechnology, Pharmaceuticals, Health
2025-10-15 3:51 PM EDT | Hemostemix Inc.
PharmaTher Announces KetAImine(TM) - AI Discovery Platform to Expand the Ketamine Portfolio, Enable Earlier Partnering, and Fast-Track 505(b)(2) NDA Filings
Toronto, Ontario--(Newsfile Corp. - October 15, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the pharmaceutical potential of ketamine, today announced KetAImine™, a proprietary ketamine repurposing and discovery platform designed to create, prioritize, and de-risk new ketamine indications and combination therapies across therapeutic areas—forming a scalable pipeline for
Biotechnology, Pharmaceuticals
2025-10-15 8:00 AM EDT | PharmaTher Holdings Ltd.
Kiora Pharmaceuticals to Participate in the 2025 Maxim Growth Summit and Eyecelerator @ AAO 2025
Encinitas, California--(Newsfile Corp. - October 15, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that it will participate in an ophthalmology panel at the upcoming 2025 Maxim Growth Summit in New York and give an overview of its development pipeline at Eyecelerator @ AAO 2025 in Orlando. Maxim Growth Summit Ophthalmology Panel Details Title: A vision of innovation; Advances in biotechnology have spurred innovation in the manageme
Biotechnology, Pharmaceuticals
2025-10-15 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
TempraMed to Commence Trading on the Canadian Securities Exchange Under Symbol "VIVI", Today, October 15, 2025
Vancouver, British Columbia--(Newsfile Corp. - October 15, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company") is pleased to announce that it has received approval to list its common shares (the "Common Shares") on the Canadian Securities Exchange ("CSE"). Trading is expected to commence on CSE under symbol "VIVI" at the open of markets on October 15, 2025. Further, the board of directors (the "Board") of the Compa
Technology, Biotechnology, Pharmaceuticals, Health
2025-10-15 7:00 AM EDT | TempraMed Technologies Ltd
CBIH Announces Women-First Fertility Innovation Built on Nanoemulsion Delivery
Houston, Texas--(Newsfile Corp. - October 13, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) today announced the addition of a patent-pending nanoemulsion formulation to its growing portfolio, developed to support female fertility and reproductive function in women of advanced maternal age (35+). CBIH believes this innovation should expand evidence-based options for patients and partners. As age is a key determinant of reproductive outcomes—and first births
Biotechnology, Pharmaceuticals, Cannabis, Health
2025-10-13 7:00 AM EDT | Cannabis Bioscience International Holdings
PreveCeutical Announces Results from Annual General and Special Meeting and Increase to Size of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - October 10, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that all resolutions presented at the Company's annual general and special meeting (the "Meeting") held on Friday, October 10, 2025, including the following: the election of Stephen Van Deventer, Makarand Jawadekar, Kathlee
Biotechnology, Pharmaceuticals, Health
2025-10-10 4:00 PM EDT | PreveCeutical Medical Inc.
TempraMed Receives Final Receipt for Prospectus and Closes Reverse Takeover Transaction of TempraMed Israel
Vancouver, British Columbia--(Newsfile Corp. - October 10, 2025) - TempraMed Technologies Ltd. (the "Company") is pleased to announce that the Company has filed and obtained a receipt on September 29, 2025, for its final long form prospectus dated September 25, 2025 (the "Prospectus"), with the British Columbia Securities Commission and is now a reporting issuer in the Province of British Columbia, effective as of September 29, 2025. The Prospectus was filed for, among other thi
Technology, Biotechnology, Pharmaceuticals, Health
2025-10-10 7:00 AM EDT | TempraMed Technologies Ltd
Global Hemp Group Applies for Partial Revocation Order and Announces Proposed Financing
Vancouver, British Columbia--(Newsfile Corp. - October 9, 2025) - Global Hemp Group Inc. (CSE: GHG) (OTC Pink: GBHPF) (FSE: GHG0) ("GHG" or the "Company") announces that it has applied to the British Columbia Securities Commission ("BCSC") for a partial revocation order (the "Partial Revocation Order") in connection with the failure-to-file cease trade order ("FFCTO") issued against the Company on April 15, 2025, for failing to file certain continu
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Cannabis
2025-10-09 9:29 AM EDT | Global Hemp Group Inc.
Hemostemix Files for Ethics Approval of its Study of Vascular Dementia
Calgary, Alberta--(Newsfile Corp. - October 9, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has filed its Institutional Review Board (IRB) application for approval of its Phase 1 clinical trial titled "Treatment of Vascular Cognitive Impairment and Dementia with Angiogenic Cell Precursors (ACP-01)." The 102-page submission marks a critical milestone in expanding the therapeutic reach of ACP
Biotechnology, Pharmaceuticals, Health
2025-10-09 9:03 AM EDT | Hemostemix Inc.
InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - October 9, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the appointment of Mr. Neil Klompas, CPA, CA to its Board of Directors, effective immediately. Mr. Klompas brings over 30 years of experience in healthcare and biotechnology across operational
Biotechnology, Pharmaceuticals
2025-10-09 8:30 AM EDT | InMed Pharmaceuticals
Neural Portfolio Company Hanf.com Reports Strong Fiscal 2024 Results with 65% Revenue Growth, Positive Cash Flow and Double-Digit Operating Margin; Continued Growth in 2025; First Half Revenues Up 31% Year-Over-Year
Toronto, Ontario--(Newsfile Corp. - October 8, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on therapeutic solutions for mental health conditions, together with its portfolio company CWE European Holdings Inc. ("CWE", operating as Hanf.com), one of Germany's leading hemp- and CBD-based retail platforms, is pleased to report the audited financial results of Hanf.com for the fis
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-10-08 9:37 AM EDT | Neural Therapeutics Inc.
PharmaTher Provides Update on Ketamine Program for LID-Parkinson's Disease
Phase 3 program targeting a potential US$2.2B U.S. market opportunity 505(b)(2) regulatory path leveraging prior human data to reduce risk, cost, and time FDA-reviewed CMC package validated through prior ANDA approval Patent coverage to 2036 for ketamine in Parkinson's and related motor disorders Active pharmaceutical partnering discussions Upcoming catalysts (Q4 2025 - Q2 2026):
Biotechnology, Pharmaceuticals
2025-10-08 8:00 AM EDT | PharmaTher Holdings Ltd.
Genix Pharmaceuticals Issues Clarification to Previously Announced Private Placement Terms
Vancouver, British Columbia--(Newsfile Corp. - October 7, 2025) - Genix Pharmaceuticals Corporation (TSXV: GENX) ("GENIX" or the "Company") wishes to clarify an error in its news release dated September 04, 2025, regarding the Company's recently closed non-brokered private placement. The previous release incorrectly stated that the Units were issued at a price of $0.10 per Unit.
Biotechnology, Pharmaceuticals, Health
2025-10-07 5:48 PM EDT | Genix Pharmaceuticals Corp.
Hemostemix's Insider Lead Order of $330,000 Private Placement
Calgary, Alberta--(Newsfile Corp. - October 7, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce a lead order of $330,000 for a non brokered private placement of up to $700,000. Purchasers may subscribe for Units at $0.11. Each Unit consists of one Common Share and one Warrant. Each Warrant may be exercised by the holder to acquire one Common Share at $0.15 for a period of two years from the Closing Date, subje
Biotechnology, Pharmaceuticals, Health
2025-10-07 10:05 AM EDT | Hemostemix Inc.
Cannabis Bioscience International Holdings, Inc. Appoints Veteran Financier Andy Trivedi to Its Board of Directors, Strengthening Capital Strategy and Growth Outlook
Houston, Texas--(Newsfile Corp. - October 6, 2025) - Cannabis Bioscience International Holdings, Inc., (OTCID: CBIH), a publicly traded biomedical cannabis research and development company listed on the OTC Markets under the ticker symbol CBIH, today announced the appointment of Mr. Andy Trivedi, MBA, to its Board of Directors. The addition of Mr. Trivedi marks a strategic step forward in the Company's mission to scale operations, expand access to capital, and enhance long-term shareholder va
Biotechnology, Pharmaceuticals, Cannabis, Health
2025-10-06 7:00 AM EDT | Cannabis Bioscience International Holdings
Optimi Health's Psilocybin Capsules Selected for Medibank Insurance Program
Vancouver, British Columbia--(Newsfile Corp. - October 6, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian GMP-compliant manufacturer of MDMA and psilocybin, today announced that its 5mg naturally-derived psilocybin capsules have been selected for inclusion in Medibank's psychotherapy program, an AUD $10 million insurance-backed initiative that has now been expanded to cover Treatment-Resistant Depression ("TRD
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-10-06 7:00 AM EDT | Optimi Health Corp.
Defence Therapeutics to Attend CPHI Worldwide in Frankfurt, October 28-30, 2025
Montreal, Quebec--(Newsfile Corp. - October 6, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce its participation at CPHI Worldwide 2025, taking place in Frankfurt, Germany from October 28-30, 2025. At this premier gathering and global trade fair of pharmaceutical leaders, Defence looks forward to engaging with potential partners acro
Biotechnology, Pharmaceuticals, Health
2025-10-06 3:15 AM EDT | Defence Therapeutics Inc.
Canadian-made Stable Isotopes: TMC Group Attends EANM 2025 to Strengthen Global Supply Chains
Vancouver, British Columbia--(Newsfile Corp. - October 2, 2025) - TMC Group, a manufacturer of high-purity stable isotopes, is attending the European Association of Nuclear Medicine (EANM) 2025 Annual Congress, October 4-8 in Barcelona. TMC Group's enriched stable isotopes have been supporting groundbreaking scientific research and innovation around the world since 2004. "We've been quietly providing a safe, reliable supply of enriched stable isotopes to world-leading researchers and li
Technology, Biotechnology, Chemical, Pharmaceuticals
2025-10-02 10:00 AM EDT | TMC Group
Defence Therapeutics Appoints Dr. Mark Lambermon as Head of Quality and Operations
Montreal, Quebec--(Newsfile Corp. - October 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce the appointment of Mark Lambermon, PhD, as Head of Quality and Operations. Dr. Lambermon brings over 20 years of experience spanning pharmaceutical R&D, biotech innovation, and commercial manufacturing, with a proven track record in building
Biotechnology, Pharmaceuticals, Health
2025-10-02 3:15 AM EDT | Defence Therapeutics Inc.
ENTERO THERAPEUTICS (ENTO) Acquires 100% of GRID AI, a Grid-Edge AI Platform Optimizing Next-Gen Power Demand
Boca Raton, Florida--(Newsfile Corp. - October 1, 2025) - Entero Therapeutics, Inc. (NASDAQ: ENTO) ("ENTO" or the "Company") today announced it has acquired 100% of GRID AI Corp ("GRID AI"), a grid-edge, AI-driven software and device platform that enables utilities, retailers, and large power users to dynamically manage load and distributed energy resources ("DERs"). Over $50 million has been invested since 2019 to commercialize this revolutionary autonomous platform delivering Dynamic
Biotechnology, Pharmaceuticals
2025-10-01 8:30 AM EDT | Entero Therapeutics, Inc.